Drilldown: Medicines

None · Codeine · 1,4-Butanediol · 1B-LSD · 1cP-LSD · 1P-LSD · 1V-LSD · 2-AI · 2-FA · 2-FDCK · 2-FMA · 25B-NBOH · 25B-NBOMe · 25C-NBOH · 25C-NBOMe · 25I-NBOH · 25I-NBOMe · 25N-NBOMe · 2C-B · 2C-B-FLY

Other values:

Search

None (2) · (multiple, generic dominant) (1) · Relafen (1)

Analgesic (2) · Classic Psychedelic (1) · Lysergamide (1) · Opioid (2) · Prodrug (1) · Research material (1) · [[:Category:Acetic_acid_derivatives|Acetic acid derivative]] (1) · [[:Category:NSAIDs|Non-steroidal anti-inflammatory drug (NSAID)]] (1)

Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) · Prodrug of LSD; 5-HT2A agonist (1) · Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1) · '"`UNIQ--vote-000011F4-QINU`"' Like all NSAIDs, raises CV thrombotic risk modestly (FDA 2014/2015 advisory) and produces GI, renal, hypertensive, and platelet-inhibitory effects characteristic of the class'"`UNIQ--ref-000011F5-QINU`"'. (1)

None (2) · Mild to moderate pain; cough suppression (low-dose). (1) · '"`UNIQ--vote-000011F6-QINU`"', '"`UNIQ--vote-000011F7-QINU`"', '"`UNIQ--vote-000011F8-QINU`"' (1)

None (2) · 1000 mg PO once daily; 500-2000 mg/d in single or divided doses (1) · Adult: 15–60 mg every 4 hours as needed. (1)

None (2) · 500, 750 mg tablets (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)

None (2) · 2000 mg/d (1) · 360 mg/day (1)

None (2) · Oral (1) · PO (only formulation marketed in the US). (1)

None (2) · 30–60 min (PO) (1) · Analgesia within hours; anti-inflammatory effect over days (1)

None (2) · 24 hours (1) · 4–6 hours (1)

None (2) · 2.5–3 hours (1) · ~24 hours (6-methoxy-2-naphthylacetic acid, the active metabolite)'"`UNIQ--ref-000011F9-QINU`"' (1)

None (2) · ~38% (oral; non-acidic prodrug improves GI tolerability over many other NSAIDs)'"`UNIQ--ref-000011FA-QINU`"' (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1)

None (2) · Avoid after 20 weeks (NSAID-class FDA 2020 advisory on fetal renal injury and oligohydramnios with second/third-trimester use).<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1)

None (2) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1) · [[USLegal:Prescription only|Rx-only]] in US. Carries the NSAID-class '''Boxed Warning''' for cardiovascular thrombotic events and serious GI bleeding'"`UNIQ--ref-000011FB-QINU`"' (1)